Evaluation of [18F]Fluoroethyl Triazole Labelled [Tyr3]-Octreotate Analogues for the Imaging of Neuroendocrine Tumours.

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

May 14, 2014

Primary Completion Date

October 17, 2018

Study Completion Date

October 17, 2018

Conditions
Neuroendocrine Tumors
Interventions
DRUG

[18F]-FET-βAG-TOCA

Single I.V. administration of a \[18F\]fluoroethyl triazole \[Tyr3\]Octreotate (\[18F\]-FET-βAG-TOCA). Patients will receive a maximum injected dose of 370MBq and will subsequently undergo PET/CT imaging.

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Imperial College Healthcare NHS Trust

OTHER

collaborator

Royal Marsden NHS Foundation Trust

OTHER

collaborator

University of Manchester

OTHER

collaborator

The Christie NHS Foundation Trust

OTHER

collaborator

Invicro

OTHER

collaborator

Newcastle University

OTHER

lead

Imperial College London

OTHER